Results 11 to 20 of about 15,148 (196)

Targeted therapy of RET fusion-positive non-small cell lung cancer

Frontiers in Oncology, 2022
Lung cancer has very high morbidity and mortality worldwide, and the prognosis is not optimistic. Previous treatments for non-small cell lung cancer (NSCLC) have limited efficacy, and targeted drugs for some gene mutations have been used in NSCLC with ...
Zixiong Shen, Binxu Qiu, Lin Li, Bo Yang, Guanghu Li   +4 more
doaj   +1 more source

RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation

Disease Models & Mechanisms, 2021
Multi-kinase RET inhibitors, such as cabozantinib and RXDX-105, are active in lung cancer patients with RET fusions; however, the overall response rates to these two drugs are unsatisfactory compared to other targeted therapy paradigms.
Takuo Hayashi, Igor Odintsov, Roger S. Smith, Kota Ishizawa, Allan J. W. Liu, Lukas Delasos, Christopher Kurzatkowski, Huichun Tai, Eric Gladstone, Morana Vojnic, Shinji Kohsaka, Ken Suzawa, Zebing Liu, Siddharth Kunte, Marissa S. Mattar, Inna Khodos, Monika A. Davare, Alexander Drilon, Emily Cheng, Elisa de Stanchina, Marc Ladanyi, Romel Somwar   +21 more
doaj   +1 more source

Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient

Frontiers in Oncology, 2022
The identification of receptor-tyrosine kinase gene (RET) fusions in lung cancer has become crucial owing to actionable events that predict responsiveness to tyrosine kinase inhibitors (TKIs).
Sha-Sha Wang, Fang Wang, Zhen Zeng, Fang Gao, Huan-Huan Liu, Hui-Na Wang, Yi Hu, Hai-Feng Qin   +7 more
doaj   +1 more source

Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue

Frontiers in Oncology, 2021
Molecular drugs targeting mutated or rearranged oncogene drivers have become one of the standard recognized treatments in patients with advanced and recurrent non-small cell lung cancer. RET is located in the long arm of human chromosome 10 and encodes a
Shinkichi Takamori, Taichi Matsubara, Naoki Haratake, Gouji Toyokawa, Takatoshi Fujishita, Ryo Toyozawa, Kensaku Ito, Masafumi Yamaguchi, Kenichi Taguchi, Tatsuro Okamoto, Takashi Seto   +10 more
doaj   +1 more source

ESMO Updates the Guidelines for the Diagnosis of RET-Altered Cancer to Herald a New Era in Targeted Therapy

healthbook TIMES. Oncology Hematology, 2021
The RET gene encodes a tyrosine kinase receptor that regulates cell survival and proliferation by triggering key downstream pathways.1 RET gene mutations and RET gene fusions are involved in the pathogenesis of lung, thyroid and other cancers.
Alfredo Addeo, Frank Stenner
doaj   +2 more sources

Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer

Frontiers in Oncology, 2023
The LIBRETTO-001 trial demonstrated the activity of the selective rearrangement during transfection (RET) inhibitor selpercatinib in advanced RET fusion-positive non-small cell lung cancer (NSCLC) and resulted in the drug’s approval for this indication ...
Jonathan W. Goldman, Lynette M. Sholl, Sanja Dacic, Michael C. Fishbein, Yonina R. Murciano-Goroff, Ravi Rajaram, Sylwia Szymczak, Anna M. Szpurka, Bo H. Chao, Alexander Drilon, Alexander Drilon   +10 more
doaj   +1 more source

Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report

Frontiers in Oncology, 2023
RET fusions occur in 1–2% of non-small cell lung cancer. Selpercatinib and pralsetinib are selective RET inhibitors with significant improvement of outcome in patients with tumor harboring RET fusion; however, resistance mechanisms appear frequently ...
Caio Abner Leite, Raíssa Pierri Carvalho, Felipe Marques da Costa, Augusto Kreling Medeiros, Fabio Augusto Schutz, William Nassib William, William Nassib William   +6 more
doaj   +1 more source

Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma. [PDF]

Oncologist
Blake McKinley, Jason S Starr
exaly   +2 more sources

Advances in the Treatment of RET Fusion-positive Advanced Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2021
Rearranged during transfection (RET) fusions are found in 0.7% to 2% of non-small cell lung cancer (NSCLC). Fusions between RET gene and other domains represent the distinct biological and clinicopathological subtypes of NSCLC.
Qingyun GAO, Junwei SU, Faman XIAO, Xiaocheng LIN, Jinji YANG   +4 more
doaj   +1 more source

Systematic population-based identification of NTRK and RET fusion-positive thyroid cancers

European Thyroid Journal, 2023
Objective: The aim of the study was to identify patients with NTRK fusion-positive or RET fusion/mutation-positive thyroid cancers, who could benefit from neurotrophic tyrosine kinase receptor (NTRK) or receptor tyrosine kinase (RET) inhibitors ...
Markus Eszlinger, Paul Stewardson, John B McIntyre, Adrian Box, Moosa Khalil, Martin Hyrcza, Konstantin Koro, Dean Ruether, Jiahui Wu, Ralf Paschke   +9 more
doaj   +1 more source